Biogen Inc. (BIIB): Price and Financial Metrics


Biogen Inc. (BIIB): $305.15

1.70 (+0.56%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BIIB to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BIIB POWR Grades

  • BIIB scores best on the Quality dimension, with a Quality rank ahead of 96.52% of US stocks.
  • The strongest trend for BIIB is in Quality, which has been heading up over the past 179 days.
  • BIIB ranks lowest in Momentum; there it ranks in the 23rd percentile.

BIIB Stock Summary

  • BIIB has a higher market value than 94.52% of US stocks; more precisely, its current market capitalization is $43,168,740,891.
  • BIOGEN INC's stock had its IPO on September 17, 1991, making it an older stock than 84.73% of US equities in our set.
  • Over the past twelve months, BIIB has reported earnings growth of 232.65%, putting it ahead of 92.68% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to BIOGEN INC are STM, KLAC, UMC, GRMN, and BGNE.
  • BIIB's SEC filings can be seen here. And to visit BIOGEN INC's official web site, go to www.biogen.com.

BIIB Valuation Summary

  • In comparison to the median Healthcare stock, BIIB's price/earnings ratio is 36.91% lower, now standing at 14.1.
  • BIIB's EV/EBIT ratio has moved down 24.3 over the prior 243 months.

Below are key valuation metrics over time for BIIB.

Stock Date P/S P/B P/E EV/EBIT
BIIB 2022-11-01 3.9 3.2 14.1 11.1
BIIB 2022-10-31 3.9 3.2 14.2 11.3
BIIB 2022-10-28 4.0 3.2 14.3 11.3
BIIB 2022-10-27 3.9 3.1 14.0 11.1
BIIB 2022-10-26 3.9 3.2 14.1 11.2
BIIB 2022-10-25 3.8 3.1 13.8 10.9

BIIB Growth Metrics

    Its 5 year net income to common stockholders growth rate is now at 58.77%.
  • The 2 year cash and equivalents growth rate now stands at -32.49%.
  • Its 3 year net income to common stockholders growth rate is now at -68.93%.
BIIB's revenue has moved down $2,509,200,000 over the prior 52 months.

The table below shows BIIB's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 10,363.2 2,397.6 2,864.7
2022-06-30 10,633.6 2,541.9 2,059.2
2022-03-31 10,819.5 3,032.7 1,449.7
2021-12-31 10,981.7 3,639.9 1,556.1
2021-09-30 11,100.5 2,434.5 1,545.8
2021-06-30 11,697.7 2,810.3 1,918.1

BIIB's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BIIB has a Quality Grade of B, ranking ahead of 87.69% of graded US stocks.
  • BIIB's asset turnover comes in at 0.459 -- ranking 97th of 680 Pharmaceutical Products stocks.
  • ZSAN, ARMP, and HGEN are the stocks whose asset turnover ratios are most correlated with BIIB.

The table below shows BIIB's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.459 0.825 0.064
2021-06-30 0.478 0.839 0.098
2021-03-31 0.510 0.855 0.206
2020-12-31 0.531 0.866 0.283
2020-09-30 0.550 0.876 0.369
2020-06-30 0.545 0.880 0.415

BIIB Price Target

For more insight on analysts targets of BIIB, see our BIIB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $417.00 Average Broker Recommendation 1.64 (Moderate Buy)

BIIB Stock Price Chart Interactive Chart >

Price chart for BIIB

BIIB Price/Volume Stats

Current price $305.15 52-week high $307.53
Prev. close $303.45 52-week low $187.16
Day low $302.70 Volume 470,700
Day high $307.53 Avg. volume 1,284,803
50-day MA $266.30 Dividend yield N/A
200-day MA $222.28 Market Cap 43.94B

Biogen Inc. (BIIB) Company Bio


Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.(Source:Wikipedia)


BIIB Latest News Stream


Event/Time News Detail
Loading, please wait...

BIIB Latest Social Stream


Loading social stream, please wait...

View Full BIIB Social Stream

Latest BIIB News From Around the Web

Below are the latest news stories about BIOGEN INC that investors may wish to consider to help them evaluate BIIB as an investment opportunity.

BIIB or RGEN: Which Is the Better Value Stock Right Now?

BIIB vs. RGEN: Which Stock Is the Better Value Option?

Yahoo | November 23, 2022

Regeneron's (REGN) Libtayo Gets EC Nod for Cervical Cancer

Regeneron (REGN) gets EC's approval for the label expansion of PD-1 inhibitor Libtayo for the treatment of adult patients with recurrent or metastatic cervical cancer.

Yahoo | November 23, 2022

Is AMN Healthcare Services (AMN) Stock Outpacing Its Medical Peers This Year?

Here is how AMN Healthcare Services (AMN) and Biogen Inc. (BIIB) have performed compared to their sector so far this year.

Yahoo | November 23, 2022

Not All Offices Are Created Equal… You Can Profit From One Sector That’s Poised to See Demand Growth

Despite what we might see in the upcoming year with office real estate or specific companies within the life sciences industry, REITs with exposure to in-demand properties remain a great way to earn guaranteed income through it all.

TalkMarkets.com | November 22, 2022

Biogen (BIIB) Receives a Buy from Mizuho Securities

Mizuho Securities analyst Salim Syed maintained a Buy rating on Biogen (BIIB - Research Report) today and set a price target of $325.00. The company's shares opened today at $304.20.Syed covers the Healthcare sector, focusing on stocks such as Cytokinetics, Biogen, and Coherus Biosciences. According to TipRanks, Syed has an average return of -17.3% and a 35.40% success rate on recommended stocks. Currently, the analyst consensus on Biogen is a Moderate Buy with an average price target of $308.83, a 1.52% upside from current levels. In a report released on November 15, Truist Financial also maintained a Buy rating on the stock with a $350.00 price target.

Austin Angelo on TipRanks | November 21, 2022

Read More 'BIIB' Stories Here

BIIB Price Returns

1-mo 9.82%
3-mo 53.66%
6-mo N/A
1-year 25.63%
3-year 0.59%
5-year -2.11%
YTD 27.19%
2021 -2.02%
2020 -17.48%
2019 -1.39%
2018 -5.54%
2017 21.96%

Continue Researching BIIB

Want to see what other sources are saying about Biogen Inc's financials and stock price? Try the links below:

Biogen Inc (BIIB) Stock Price | Nasdaq
Biogen Inc (BIIB) Stock Quote, History and News - Yahoo Finance
Biogen Inc (BIIB) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7682 seconds.